Service de Pneumologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Centre National de Référence des Maladies Auto-Immunes et Systémiques Rares, Est/Sud-Ouest (RESO), France.
Lupus. 2021 Mar;30(3):510-513. doi: 10.1177/0961203320976982. Epub 2020 Dec 1.
Pulmonary arterial hypertension (PAH), is a rare manifestation of systemic lupus erythematosus (SLE), characterized by pulmonary arterial remodeling leading to right ventricular failure and death. To date, optimal management of SLE-associated PAH should be clarified, especially regarding the respective places of immunosuppressants and PAH vasodilator treatments.
We report the case of a 48-year-old woman with SLE and secondary Sjogren syndrome, associated with severe PAH and lupus peritonitis with massive ascites, who showed a remarkable response, both for SLE flare and PAH, to a treatment combining immunosuppressants and pulmonary arterial vasodilator treatment.
This observation highlights the interest of combining immunosuppressive therapy in SLE-PAH, whose modalities in association with PAH treatments should be clarified.
肺动脉高压(PAH)是系统性红斑狼疮(SLE)的罕见表现,其特征为肺动脉重构导致右心衰竭和死亡。迄今为止,应阐明与 SLE 相关的 PAH 的最佳治疗方法,尤其是免疫抑制剂和 PAH 血管扩张剂治疗的各自地位。
我们报告了一例 48 岁女性,患有 SLE 和继发性干燥综合征,并发严重的 PAH 和狼疮性腹膜炎伴大量腹水,联合免疫抑制剂和肺动脉血管扩张剂治疗后,SLE 发作和 PAH 均有显著缓解。
该观察结果强调了联合治疗 SLE-PAH 的重要性,其与 PAH 治疗联合的方式尚需进一步阐明。